Maykin Ho, Ph.D.

Maykin Ho brings more than 30 years of experience in the healthcare and finance industries to the Parexel Board. She is a former Partner at The Goldman Sachs Group, where she was a top-ranked biotechnology research analyst, Co-Head of U.S. Healthcare for Global Investment Research and Advisory Director for Global Investment Banking. Maykin served on Parexel’s Board of Directors when the company was publicly listed, and during Pamplona’s ownership. She is currently a Venture Partner at Qiming Venture Partners and serves on the boards of Agios Pharmaceuticals, BioMarin, FibroGen and Neumora. Previously, Maykin was a member of the Board of Directors at Grail, Inc. She holds a Ph.D. in microbiology and immunology and a Bachelor of Science in biology from the State University of New York, Downstate Medical Center. Maykin was a postdoctoral fellow at Harvard Medical School and is also a graduate of the Advanced Management Program at Duke University’s Fuqua School of Business.